MARKET

CSBR

CSBR

Champions Oncolo
NASDAQ
4.810
0.00
0.00%
Opening 09:30 07/26 EDT
OPEN
--
PREV CLOSE
4.790
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
7.14
52 WEEK LOW
4.500
MARKET CAP
65.39M
P/E (TTM)
-8.9555
1D
5D
1M
3M
1Y
5Y
1D
Champions Oncology Inc reports results for the quarter ended in April - Earnings Summary
Champions Oncology Inc reported quarterly adjusted earnings of 1 cent per share for the quarter ended in April. Revenue rose 7.1% to $14.00 million from a year ago. The company's shares had fallen by 2.4% this quarter and lost 10.2% so far this year.
Reuters · 4d ago
Weekly Report: what happened at CSBR last week (0715-0719)?
Weekly Report · 4d ago
Champions Oncology Inc <CSBR.OQ> expected to post a loss of 10 cents a share - Earnings Preview
Champions Oncology Inc CSBR.OQ expected to post a loss of 10 cents a share. The company is expected to report a 4.3% increase in quarterly revenue to $13.101 million. The one available analyst rating on the shares is 'hold'
Reuters · 07/19 21:39
CSBR Stock Earnings: Champions Oncology Beats EPS, Beats Revenue for Q4 2024
Champions Oncology reported results for the fourth quarter of 2024. The company reported earnings per share of 1 cent and revenue of $14.00 million. Champions oncology's revenue was 10.33% better than the analyst estimate for fourth quarter 2024 revenue.
Investorplace · 07/19 01:53
Champions Oncology Q4 2024 Adj EPS $0.01 Beats $(0.16) Estimate, Sales $14.001M Beat $12.692M Estimate
Champions Oncology reported quarterly earnings of $0.01 per share. The company reported quarterly sales of $14.001 million. Champions oncology beat the analyst consensus estimate of $12.692 million by 10.31%. The company's quarterly sales were up 7.11 percent from the same period last year.
Benzinga · 07/18 21:05
Champions Oncology Non-GAAP EPS of $0.01, revenue of $14M beats by $1.31M
Earnings News Champions Oncology Non-GAAP EPS of $0.01, revenue of $14M beats by $1.31M. Champions oncology, Inc. (CSBR) reports Q4 results. The company is expected to report its quarterly results on July 18.
Seeking Alpha · 07/18 20:50
CHAMPIONS ONCOLOGY Q4 GROSS MARGIN 49%
Reuters · 07/18 20:34
Craig-Hallum Sticks to Its Buy Rating for Champions Oncology (CSBR)
TipRanks · 07/16 12:59
More
About CSBR
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.

Webull offers Champions Oncology Inc stock information, including NASDAQ: CSBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSBR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CSBR stock methods without spending real money on the virtual paper trading platform.